Skip to main content
SpringerLink
Log in

Pharmacologic effects on cardiac remodeling

  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Clinical research during the past several decades has shown the importance of cardiac remodeling as a basic mechanism in the progression of heart failure. Changes in cardiac remodeling have high concordance with long-term clinical outcomes. Cardiac remodeling should be regarded as a primary target for treatment and also can serve as a reliable surrogate for clinical outcomes. Neurohormonal blockade with combination treatments that inhibit the reninangiotensin-aldosterone and sympathetic systems has proven effective in improving cardiac remodeling and clinical outcomes. Such treatment should be standard therapy for patients with left ventricular dysfunction after myocardial infarction and patients with chronic heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990, 81:1161–1172. This is a review of experimental work, which provided the background and rationale for subsequent clinical studies.

    PubMed  CAS  Google Scholar 

  2. Rouleau JL, de Champlain J, Klein M, et al.: Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993, 22:390–398.

    Article  PubMed  CAS  Google Scholar 

  3. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000, 35:569–582. This is a timely consensus statement that provides a clear definition of cardiac remodeling and perspective of clinical relevance.

    Article  PubMed  CAS  Google Scholar 

  4. Jeremy RW, Hackworthy RA, Bautovich G, et al.: Infarct artery perfusion and changes in left ventricular volume in the month after acute myocardial infarction. J Am Coll Cardiol 1987, 9:989–995.

    Article  PubMed  CAS  Google Scholar 

  5. Pirolo JS, Hutchins GM, Moore GW: Infarct expansion: pathologic analysis of 204 patients with a single myocardial infarct. J Am Coll Cardiol 1986, 7:349–354.

    Article  PubMed  CAS  Google Scholar 

  6. Touchstone DA, Beller GA, Nygaard TW, et al.: Effects of successful intravenous reperfusion therapy on regional myocardial function and geometry in humans: a topographic assessment using two-dimensional echocardiography. J Am Coll Cardiol 1989, 13:1506–1513.

    Article  PubMed  CAS  Google Scholar 

  7. Marino P, Zanolla L, Zardini P: Effect of streptokinase on left ventricular modeling and function after myocardial infarction: the GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico) Trial. J Am Coll Cardiol 1989, 14:1149–1158.

    Article  PubMed  CAS  Google Scholar 

  8. White HD, Cross DB, Elliott JM, et al.: Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994, 89:61–67.

    PubMed  CAS  Google Scholar 

  9. Jugdutt BI, Warnica JW: Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 1988, 78:906–919.

    PubMed  CAS  Google Scholar 

  10. Mahmarian JJ, Moye LA, Chinoy DA, et al.: Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomised, double-blind, placebo-controlled trial. Circulation 1998, 97:2017–2024.

    PubMed  CAS  Google Scholar 

  11. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet 1994, 343:1115–1122.

  12. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995, 345:669–682.

  13. Sharpe N, Murphy J, Smith H, Hannan S: Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988, 1:255–259. This is the first published clinical study showing that cardiac remodeling could be prevented with ACE inhibition in patients with left ventricular dysfunction after myocardial infarction.

    Article  PubMed  CAS  Google Scholar 

  14. Pfeffer MA, Lamas GA, Vaughan DE, et al.: Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988, 319:80–86.

    Article  PubMed  CAS  Google Scholar 

  15. Sharpe N, Smith H, Murphy J, et al.: Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting enzyme inhibition. Lancet 1991, 337:872–876.

    Article  PubMed  CAS  Google Scholar 

  16. Magrini F, Shimizu M, Roberts N, et al.: Converting-enzyme inhibition and coronary blood flow. Circulation 1987, 75:S1168-S1174.

    Google Scholar 

  17. Cleland JG, Henderson E, McLenachen J, et al.: Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. J Am Coll Cardiol 1991, 17:733–739.

    Article  PubMed  CAS  Google Scholar 

  18. Weber KT: Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997, 96:4065–4082.

    PubMed  CAS  Google Scholar 

  19. Yamazaki T, Komuro I, Kudoh S, et al.: Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res 1995, 77:258–265.

    PubMed  CAS  Google Scholar 

  20. Lindpaintner K, Lu W, Neidermajer N, et al.: Selective activation of cardiac angiotensinogen gene expression in post-infarction ventricular remodeling in the rat. J Mol Cell Cardiol 1993, 25:133–143.

    Article  PubMed  CAS  Google Scholar 

  21. Pfeffer MA, Braunwald E, Moy’e LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669–677. This is the first randomized controlled trial to show improved clinical outcomes with ACE inhibition after myocardial infarction; earlier studies demonstrated remodeling benefit.

    Article  PubMed  CAS  Google Scholar 

  22. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993, 342:821–828.

  23. French JK, Amos DJ, Williams BF, et al.: Effects of early captopril administration after thrombolysis on regional wall motion in relation to infarct artery blood flow. J Am Coll Cardiol 1999, 33:139–145.

    Article  PubMed  CAS  Google Scholar 

  24. Lamas GA, Flaker GC, Mitchell G, et al.: Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. Circulation 1995, 92:1101–1109.

    PubMed  CAS  Google Scholar 

  25. Sharpe DN, Murphy J, Coxon R, Hanna SF: Enalapril in patients with chronic heart failure: a placebo-controlled, randomised double-blind trial. Circulation 1984, 70:271–278.

    PubMed  CAS  Google Scholar 

  26. Konstam MA, Rousseau MF, Kronenberg MW, et al.: Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992, 86:431–438.

    PubMed  CAS  Google Scholar 

  27. Greenberg B, Quinones MA, Koilpillai C, et al.: Effects of longterm enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 1995, 91:2573–2581. The authors report that cardiac remodeling in chronic heart failure improved with ACE inhibition, an effect concordant with improved clinical outcomes in the SOLVD prevention trial.

    PubMed  CAS  Google Scholar 

  28. Konstam MA, Patten RD, Thomas I, et al.: Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J 2000, 139:1081–1087.

    Article  PubMed  CAS  Google Scholar 

  29. Cohn JN, Tognoni G: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.

    Article  PubMed  CAS  Google Scholar 

  30. Granger CB, McMurray JJ, Yusuf S, et al.: Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772–776.

    Article  PubMed  CAS  Google Scholar 

  31. McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771.

    Article  PubMed  CAS  Google Scholar 

  32. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321.

    Article  PubMed  CAS  Google Scholar 

  33. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717.

    Article  PubMed  CAS  Google Scholar 

  34. Brilla CG, Zhou G, Matsubara L, Weber KT: Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994, 26:809–820.

    Article  PubMed  CAS  Google Scholar 

  35. Hayashi M, Tsutamoto T, Wada A, et al.: Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003, 107:2559–2565.

    Article  PubMed  CAS  Google Scholar 

  36. Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700–2706. [Published erratum appears in Circulation 2001, 103:476.]

    PubMed  CAS  Google Scholar 

  37. Basu S, Senior R, Raval U, et al.: Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomised trial. Circulation 1997, 96:183–191.

    PubMed  CAS  Google Scholar 

  38. Doughty RN, Whalley GA, Walsh HA, et al.: Effects of carvedilol on left ventricular remodeling following myocardial infarction: the CAPRICORN Echocardiographic Substudy. Circulation 2004, In press. In this study, blockade with carvedilol provided additive remodeling benefit in patients with left ventricular dysfunction after myocardial infarction established during standard ACE inhibitor therapy. This effect was concordant with the clinical benefits demonstrated in the main CAPRICORN study.

  39. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385–1390.

    Article  PubMed  CAS  Google Scholar 

  40. Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349–1355.

    Article  PubMed  CAS  Google Scholar 

  41. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999, 353:2002–2007.

    Google Scholar 

  42. Doughty RN, Whalley GA, Gamble G, et al.: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischaemic heart disease: Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997, 29:1060–1066. In this study, blockade with carvedilol improved ventricular remodeling in patients with chronic heart failure receiving ACE inhibition therapy. As in other studies, this remodeling effect was concordant with clinical outcomes.

    Article  PubMed  CAS  Google Scholar 

  43. Hall SA, Cigarroa CG, Marcoux L, et al.: Time course in improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with betaadrenergic blockade. J Am Coll Cardiol 1995, 25:1154–1161.

    Article  PubMed  CAS  Google Scholar 

  44. Packer M, Antonopoulos GV, Berlin JA, et al.: Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001, 141:899–907.

    Article  PubMed  CAS  Google Scholar 

  45. Poole-Wilson PA, Swedberg K, Cleland JG, et al.: Comparison of carvedilol and metoprolol in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7–13.

    Article  PubMed  CAS  Google Scholar 

  46. Bristow MR, Gilbert EM, Abraham WT, et al.: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996, 94:2807–2816.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 671 Riddell Road, 1005, Glendowie, Auckland, New Zealand

    Norman Sharpe MD

Authors
  1. Norman Sharpe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharpe, N. Pharmacologic effects on cardiac remodeling. Curr Heart Fail Rep 1, 9–13 (2004). https://doi.org/10.1007/s11897-004-0011-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-004-0011-x

Keywords

Search

Navigation